Breast Cancer

Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.

Experts discuss various treatment options for patients with HER2-positive breast cancer, and which would benefit the most based on their characteristics.

Data from the phase 3 DESTINY-Breast09 trial presented at the 2025 ASCO Annual Meeting formed the basis of the supplemental NDA.

Oncotype DX 21-gene recurrence scores may help select certain patients who are suitable to omit radiotherapy for early-stage breast cancer.

Cryoablation, when combined with adjuvant endocrine therapy, may offer a minimally invasive outpatient strategy in older patients with breast cancer.

The safety profile of dato-DXd was consistent with previous clinical trials assessing the agent in breast cancer.

The decision is based on phase 3 DESTINY-Breast11 trial data, in which the investigational regimen displayed improved pCR vs SOC in this breast cancer population.

Combination therapy of ETX-636 plus fulvestrant is being administered to patients with HR–positive, HER2-negative breast cancer in a phase 1/2 trial.

In the phase 3 EMBER-3 trial, Guardant360 CDx was used to identify patients with ESR1-mutated advanced breast cancer who may benefit from imlunestrant.

The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.

Planned interim results from the phase 3 DESTINY-Breast05 trial showed no new safety signals with T-DXd in the trial population.

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.

Results from the phase 3 DESTINY-Breast09 trial will support the FDA’s decision on whether to approve T-DXd plus pertuzumab in frontline metastatic breast cancer.

Read an expert-led article on the latest advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative breast cancer and improving patient outcomes.

Data from the phase 3 evERA trial show a trend toward improved overall survival with giredestrant plus everolimus in this breast cancer population.

THERMAC trial results revealed that the ProSense® cryoablation system showed no complications, and the highest complete ablation rate in breast cancer.

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

The rolling submission is supported by data from the PIK3CA wild-type cohort of the phase 3 VIKTORIA-1 trial evaluating gedatolisib in advanced breast cancer.

Results from the monarchE study showed a statistically significant OS improvement with abemaciclib plus ET for patients with HR+/HER2– early breast cancer.

Tran Ho, DO, FSSO, FACS, discussed how she found her passion in breast surgical oncology and how her mentors helped her achieve success.

FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.

The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.